Abstract:The only definitive management of snake envenoming is the use of snake antivenom. Endotoxin contamination is a serious threat to the safe use of parenteral drugs. A greater understanding of the nature of limulus amebocyte lysate (LAL) test interference and use of permissible dilutions has minimized enhancement problems. Common interference issues include suboptimal pH, enzyme or protein modification, and nonspecific LAL activation. This study aimed at determining the interference factors associated with validating the antivenom sera preparations to avoid false-positive results when testing snake antivenom serum samples by the LAL method. Phase I (preliminary screening/interference assay) was performed to determine a compatible test dilution, which was then used in Phase II (inhibition-enhancement/validation study). The best approach to resolve interference issues was dilution by 1:80 (maximum valid dilution) plus a specific treatment as heat-activation at 70°C-80°C for 10 min with rehydration of LAL reagent with endotoxin-specific buffer solution.LAY ABSTRACT: Snake antivenom sera are produced by immunizing horses with repeated nonlethal doses of snake venom. Bacterial endotoxins constitute one of the major problems in the formulation of pharmaceutical products. One such method for detecting endotoxin levels is the bacterial endotoxin test (BET). However, some substances show strong interfering action with the BET that cannot be avoided by simply diluting the sample solution. In this work, the test for interfering factors was performed as two identical series of product dilutions-one spiked with 2λ and one left unspiked. The result of the interference test revealed the noninterfering dilution (NID) of the product, which was used for the actual validation. Our results showed that after treating the samples using different procedures, such as heat activation at 70-80°C for 10 min followed by centrifugation at 2000 rpm for 10 min and dilution of samples in BD100 (biodispersing agent), inhibition and enhancement up to 1:100 maximum valid dilution (MVD) were observed. Finally, to resolve this inhibition/enhancement problem, the activated sample was heated at 70-80°C for 10 min with rehydration of the Endosafe LAL reagent in an endotoxin-specific buffer solution (BG120) to block β-d-glucans and limulus amebocyte lysate (LAL) reactive material (LAL-RM).

Development and Validation of a Ligand-Binding Assay for Quantification of the F(ab')2 Antivenom of Daboia Russelii Siamensis in Human Serum and Its Application to a Phase I Clinical Study

A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar

The application of laboratory-based analytical tools and techniques for the quality assessment and improvement of commercial antivenoms used in the treatment of snakebite envenomation

Preparation of a Monoclonal Antibody Against a Kallikrein-Like Enzyme Fromagkistrodon Halys Pallasvenom and Its Application in a Pharmacokinetic Study

A Strategy for Efficient Preparation of Genus-Specific Diagnostic Antibodies for Snakebites

Comparative functional characterization and in vitro immunological cross-reactivity studies on Daboia russelii and Craspedocephalus malabaricus venom

Rapid and Efficient Enrichment of Snake Venoms from Human Plasma Using a Strong Cation Exchange Tip Column to Improve Snakebite Diagnosis

Multiplex lateral flow assay development for snake venom detection in biological matrices

A Validation Study of the Limulus Amebocyte Lysate Test as an End-Product Endotoxin Test for Polyvalent Horse Snake Antivenom

Development and Validation of an Lc-Ms/Ms Method for the Determination of Sb-505124 in Rat Plasma: Application to Pharmacokinetic Study

Acetylcholine-Binding Protein Affinity Profiling of Neurotoxins in Snake Venoms with Parallel Toxin Identification

Broad-Spectrum Detoxification of Snake Venoms with Supramolecular Materials Integrated Via Molecular Recognition and Coassembly.

Development and Validation of a Sensitive LC-MS-MS Assay for the Quantification of Betulonic Acid in Rat Plasma.

Optimizing drug discovery for snakebite envenoming via a high-throughput phospholipase A2 screening platform

Discovery and optimization of a broadly-neutralizing human monoclonal antibody against long-chain α-neurotoxins from snakes

Development and validation of a liquid chromatography tandem mass spectrometry assay for the quantitation of a protein therapeutic in cynomolgus monkey serum

Preclinical evaluation of single domain antibody efficacy in mitigating local tissue damage induced by Bothrops snake envenomation

Preparation and detection of sea snake antisera raised in rabbits

Development and Validation of an Enzyme-Linked Immunosorbent Assay for the Quantification of a Recombinant Humanized Anti-Il-4rα Monoclonal Antibody CM310 in Serum and Its Application to Pharmacokinetic Study in Sprague-Dawley Rats.

Cell Affinity Screening Combined with Nanolc-Ms/ms Based Peptidomics for Identifying Cancer Cell Binding Peptides from Bufo Bufo Gargarizans.

Evaluation of the Inhibitory Potential of Synthetic Peptides Homologous to CDR3 Regions of a Monoclonal Antibody against Bothropic Venom Serine Proteases